JP2023166388A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166388A5
JP2023166388A5 JP2023130117A JP2023130117A JP2023166388A5 JP 2023166388 A5 JP2023166388 A5 JP 2023166388A5 JP 2023130117 A JP2023130117 A JP 2023130117A JP 2023130117 A JP2023130117 A JP 2023130117A JP 2023166388 A5 JP2023166388 A5 JP 2023166388A5
Authority
JP
Japan
Prior art keywords
administered
dose
composition
mirikizumab
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023130117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023166388A (ja
JP7571225B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/024633 external-priority patent/WO2019191464A1/en
Application filed filed Critical
Publication of JP2023166388A publication Critical patent/JP2023166388A/ja
Publication of JP2023166388A5 publication Critical patent/JP2023166388A5/ja
Priority to JP2024176901A priority Critical patent/JP2025020134A/ja
Application granted granted Critical
Publication of JP7571225B2 publication Critical patent/JP7571225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023130117A 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法 Active JP7571225B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176901A JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
US62/650,314 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis
JP2020552872A JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022123689A Division JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176901A Division JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Publications (3)

Publication Number Publication Date
JP2023166388A JP2023166388A (ja) 2023-11-21
JP2023166388A5 true JP2023166388A5 (cg-RX-API-DMAC10.html) 2024-05-14
JP7571225B2 JP7571225B2 (ja) 2024-10-22

Family

ID=66429483

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020552872A Active JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A Active JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法
JP2024176901A Pending JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020552872A Active JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176901A Pending JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Country Status (29)

Country Link
US (2) US12152072B2 (cg-RX-API-DMAC10.html)
EP (3) EP4752157A2 (cg-RX-API-DMAC10.html)
JP (4) JP7119114B2 (cg-RX-API-DMAC10.html)
KR (1) KR102552693B1 (cg-RX-API-DMAC10.html)
CN (1) CN111936165A (cg-RX-API-DMAC10.html)
AU (3) AU2019243283C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020018099A2 (cg-RX-API-DMAC10.html)
CA (1) CA3095297A1 (cg-RX-API-DMAC10.html)
DK (2) DK3773715T3 (cg-RX-API-DMAC10.html)
EA (1) EA202091989A1 (cg-RX-API-DMAC10.html)
ES (2) ES3063700T3 (cg-RX-API-DMAC10.html)
FI (2) FI4327866T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20240904T1 (cg-RX-API-DMAC10.html)
HU (1) HUE067445T2 (cg-RX-API-DMAC10.html)
IL (2) IL312807B2 (cg-RX-API-DMAC10.html)
LT (2) LT3773715T (cg-RX-API-DMAC10.html)
MA (2) MA52216B1 (cg-RX-API-DMAC10.html)
MD (2) MD3773715T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020010269A (cg-RX-API-DMAC10.html)
MY (1) MY202368A (cg-RX-API-DMAC10.html)
PL (2) PL4327866T3 (cg-RX-API-DMAC10.html)
PT (2) PT3773715T (cg-RX-API-DMAC10.html)
RS (2) RS65661B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009526RA (cg-RX-API-DMAC10.html)
SI (2) SI4327866T1 (cg-RX-API-DMAC10.html)
TW (2) TWI744617B (cg-RX-API-DMAC10.html)
UA (1) UA128578C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019191464A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202005388B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
IL295545A (en) * 2020-02-14 2022-10-01 Janssen Biotech Inc Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
US20220259301A1 (en) * 2021-01-06 2022-08-18 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2022251623A1 (en) * 2021-05-28 2022-12-01 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
KR20240103043A (ko) * 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
AU2023383916A1 (en) * 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
JP7863690B2 (ja) 2023-03-10 2026-05-21 イーライ リリー アンド カンパニー 潰瘍性大腸炎を治療する方法
JP2026521705A (ja) * 2023-06-16 2026-07-01 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド 炎症性腸疾患の治療における組換え抗インターロイキン23p19サブユニット抗体の使用
AU2025218720A1 (en) 2024-02-06 2026-05-21 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2613818C (en) * 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
JP7516250B2 (ja) * 2018-03-05 2024-07-16 ヤンセン バイオテツク,インコーポレーテツド 抗il-23特異的抗体を用いたクローン病の治療方法

Similar Documents

Publication Publication Date Title
JP2025020134A5 (cg-RX-API-DMAC10.html)
Zhang et al. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential
JP2023541432A5 (cg-RX-API-DMAC10.html)
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
NZ598534A (en) Dosage regimen of an s1p receptor modulator
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2025148449A5 (cg-RX-API-DMAC10.html)
JP2023500020A5 (cg-RX-API-DMAC10.html)
JP2002530353A5 (cg-RX-API-DMAC10.html)
Meng et al. Use of glucocorticoid in treatment of severe acute respiratory syndrome cases
JP2023020885A5 (cg-RX-API-DMAC10.html)
JP2022550828A5 (cg-RX-API-DMAC10.html)
JP2024531799A5 (cg-RX-API-DMAC10.html)
Rea et al. Hypotensive action of chlorpromazine
JP2019178177A5 (cg-RX-API-DMAC10.html)
CN120324408A (zh) 黄芩素对s蛋白联合lps诱导的急性肺损伤的治疗作用
JP2021528399A5 (cg-RX-API-DMAC10.html)
TW202202136A (zh) 組合物在治療腦卒中的用途
CN112043718A (zh) 异甘草酸镁在制备治疗结肠炎药物中的应用
JP2016510738A5 (cg-RX-API-DMAC10.html)
CN108567768B (zh) 对-[(二丙氨基)磺酰基]苯甲酸的医药用途
CN114796246B (zh) 一种用于治疗心力衰竭的药物及其用途
RM et al. Hydroxycobalamin Administration in the Treatment of Calcium Channel Blocker-Induced Vasoplegia: A Case Report
US10314876B2 (en) Method for treating diabetes mellitus caused by pancreatitis
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta